-
公开(公告)号：US11710536B2
公开(公告)日：2023-07-25
申请号：US17735494
申请日：2022-05-03
CPC分类号： G16B20/00 , C12N5/0693 , C12N5/0694 , C12N9/22 , C12N15/1058 , C12N15/1089 , C12N15/1096 , C12N15/11 , C12N15/86 , G06N20/00 , G16B40/20 , C12N2310/20 , C12N2740/15043 , C12N2800/80
摘要： The present disclosure provides methods and systems for identification of genomic regions for therapeutic targeting. A method for identifying one or more genomic regions for therapeutic targeting, which may facilitate re-programming of a cell from one phenotypic state to another, may comprise: providing single-cell RNA-seq data for a plurality of diseased cells and a plurality of normal cells of a cell type; mapping the single-cell RNA-seq data for the plurality of diseased cells and the plurality of normal cells into a latent space corresponding to a plurality of phenotypic states of the cell type; identifying, based at least in part on a topology of the latent space, the one or more genomic regions for therapeutic targeting; and electronically outputting the one or more genomic regions for therapeutic targeting.
-
82.发明申请公开(公告)号：US20190212325A1
公开(公告)日：2019-07-11
申请号：US15773400
申请日：2016-11-04
申请人： VIVIA BIOTECH, S.L
发明人： Juan Antonio BALLESTEROS NOBELL , Teresa BENNETT , Daniel PRIMO RAMOS , Paolo PROSPERO GHIA , Ana Belén ESPINOSA OQUILLAS , Julián GORROCHATEGUI GUILLÉN , Alicia ROBLES MATEOS , Pilar HERNÁNDEZ CAMPO
CPC分类号： G01N33/5011 , C12N5/0694 , C12N2500/40 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2313 , C12N2501/2315 , C12N2501/2321 , C12N2501/998 , C12N2501/999 , C12N2502/30 , C12N2503/02 , C12N2513/00 , G01N33/5044 , G01N33/5088
摘要： The invention presented here relates to a method for producing an artificial environment of primary cell populations, particularly an artificial tumor environment of primary tumor cell populations and its use in an ex vivo method to test the cellular responsiveness of primary tumor cell populations to a drug or drugs. The method of the invention comprises incubation of the primary tumor cells with the artificial tumor environment and the drug or drugs and analyze the response of the primary tumor cell populations. The incubation of the primary tumor cells with the artificial tumor environment, enhances the viability of said tumor cells and/or induces greater levels of tumor cell proliferation and, consequently, increases the sensitivity and accuracy of the test with regard to the drug/s assayed.
-
公开(公告)号：US09994819B2
公开(公告)日：2018-06-12
申请号：US15154653
申请日：2016-05-13
发明人： Peiman Hematti , Jaehyup Kim
CPC分类号： C12N5/0647 , A61K35/28 , A61K2035/124 , C12N5/0676 , C12N5/0693 , C12N5/0694 , C12N2502/1157 , C12N2502/1358 , C12N2506/02 , C12N2506/22 , G01N33/5073
摘要： The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.
-
公开(公告)号：US20180045708A1
公开(公告)日：2018-02-15
申请号：US15790981
申请日：2017-10-23
发明人： Georgi HVICHIA
CPC分类号： B01L3/502753 , B01L2200/0652 , B01L2200/12 , B01L2300/0816 , B01L2300/0864 , C12N5/0694 , C12Q1/24 , G01N15/0272 , G01N33/491 , G01N33/574 , G01N2015/0288
摘要： The disclosure relates to an apparatus for segregating particles on the basis of their ability to flow through a stepped passageway. At least some of the particles are unable to pass through a narrower passageway bounded by a segregating step, resulting in segregation of the particles. The breadth of the leading edge of at least one step of the apparatus is significantly greater than the overall width of the passageway in which the step occurs, permitting high and rapid sample throughput. The apparatus and methods described herein can be used to segregate particles of a wide variety of types. By way of example, they can be used to segregate circulating tumor cells from a human blood sample.
-
公开(公告)号：US20180010117A1
公开(公告)日：2018-01-11
申请号：US15642165
申请日：2017-07-05
发明人： David Paschon
CPC分类号： C12N15/102 , A01K2217/072 , A01K2227/105 , A01K2267/0393 , A61K9/0048 , A61K38/465 , C12N5/0694 , C12N9/22 , C12N15/11 , C12N2310/20 , C12N2510/04 , C12N2750/14143 , C12Y301/00
摘要： Disclosed herein are methods and compositions for inactivating mutant genes associated with LCA, using engineered nucleases comprising a DNA binding domain and a cleavage domain or cleavage half-domain in conditions promoting the cleavage of the mutant genes. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases, and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
-
公开(公告)号：US09861983B2
公开(公告)日：2018-01-09
申请号：US15434223
申请日：2017-02-16
发明人： Georgi Hvichia
CPC分类号： B01L3/502753 , B01L2200/0652 , B01L2200/12 , B01L2300/0816 , B01L2300/0864 , C12N5/0694 , C12Q1/24 , G01N15/0272 , G01N33/491 , G01N33/574 , G01N2015/0288
摘要： The disclosure relates to an apparatus for segregating particles on the basis of their ability to flow through a stepped passageway. At least some of the particles are unable to pass through a narrower passageway bounded by a segregating step, resulting in segregation of the particles. The breadth of the leading edge of at least one step of the apparatus is significantly greater than the overall width of the passageway in which the step occurs, permitting high and rapid sample throughput. The apparatus and methods described herein can be used to segregate particles of a wide variety of types. By way of example, they can be used to segregate circulating tumor cells from a human blood sample.
-
公开(公告)号：US09783785B2
公开(公告)日：2017-10-10
申请号：US12973153
申请日：2010-12-20
申请人： Cameron K. Tebbi
发明人： Cameron K. Tebbi
IPC分类号： C40B30/04 , C12N5/09 , G01N33/574 , G01N33/68 , C12Q1/70
CPC分类号： C12N5/0694 , G01N33/57426 , G01N33/6854 , G01N2333/05 , G01N2333/38
摘要： A diagnostic test is described using Aspergillus flavus fungal cultures, EBV or their combination to induce leukemic cell surface markers in mononuclear cells of former or current leukemia patients. Unlike aflotoxin, which indiscriminately induces leukemic transformation, the compositions used were specific to leukemia-predisposed patients, but not other cancers or normal controls. The test identifies survivors of ALL and can detect propensity for development of leukemia in susceptible individuals. An ELISA technique using the described fungal products or EBV and combination can detect individuals with history of leukemia and not controls. These findings have implications for the etiology of leukemias and lymphomas and use for mass screening, detection of susceptible individuals to leukemia and potential vaccination.
-
公开(公告)号：US20170260510A1
公开(公告)日：2017-09-14
申请号：US15067991
申请日：2016-03-11
发明人： Mark A. Dawson , Chun Yew Fong
CPC分类号： C12N5/0694 , C12N2501/065 , G01N33/5011 , G01N33/5044 , G01N33/5073
摘要： Bromodomain and extra terminal protein (BET) resistant leukemic cell lines and methods for producing such cell lines are described as are methods for using such cell lines in screening assays to identify therapeutic agents. The cell lines can be generated from haematopoietic stem and progenitor cells (HSPCs) that are clonally enriched by serially exposing c-kit positive cells to a BET inhibitor.
-
公开(公告)号：US20170247662A1
公开(公告)日：2017-08-31
申请号：US15465638
申请日：2017-03-22
IPC分类号： C12N5/09 , G03F7/038 , G03F7/20 , G03F7/32 , B01D39/10 , G03F7/42 , C08J5/12 , G01N33/49 , G01N1/40 , G03F7/039 , G03F7/40
CPC分类号： C12N5/0694 , B01D39/10 , B22D25/02 , B22D29/00 , C08J5/121 , C08J2300/12 , G01N1/4077 , G01N33/49 , G01N2001/4088 , G03F7/038 , G03F7/039 , G03F7/2004 , G03F7/322 , G03F7/405 , G03F7/428 , Y10T29/49 , Y10T156/10
摘要： Provided are a cancer cell-trapping metal filter which has a high opening ratio, a cancer cell-trapping metal filter sheet, a cancer cell-trapping device using the cancer cell-trapping filter, and manufacturing methods therefor.According to a cancer cell-trapping metal filter 1, openings of connected through-holes 12 that are formed in a metal sheet 11 have a wave shape, and thus it is possible to extract a CTC from other components by utilizing a hole diameter on a short-side side of the openings, and it is possible to make the connected through-holes be closer to each other due to the wave shape while maintaining a CTC trapping ability. Accordingly, it is possible to further improve the opening ratio in the cancer cell-trapping metal filter 1.
-
公开(公告)号：US20170232146A1
公开(公告)日：2017-08-17
申请号：US15585653
申请日：2017-05-03
CPC分类号： A61L27/3834 , A61L27/225 , A61L27/3608 , A61L27/3804 , A61L27/3808 , A61L27/3847 , A61L27/54 , A61L2300/414 , A61L2300/418 , A61L2300/42 , A61L2300/426 , A61L2300/64 , A61L2430/02 , A61L2430/40 , C12N5/0669 , C12N5/0694 , C12N2502/30 , C12N2513/00 , C12N2533/56 , G01N33/5011 , G01N33/5082 , G01N33/5088
摘要： A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
-
-
-
-
-
-
-
-
-
搜索结果
228 条记录 (耗时 0.029 秒)
